Organisation chart: Advisory functions
Submitted by Anonymous (not verified) on 16 April 2024 - 8:21
Organisation chart: Advisory functions
Organisation chart: Stakeholders and Communication
Submitted by Anonymous (not verified) on 16 April 2024 - 8:16
Organisation chart: Stakeholders and Communication
Template - Application for transfer of marketing authorisation from transferor to transferee, cover letter
Submitted by Anonymous (not verified) on 15 April 2024 - 16:01
Template - Application for transfer of marketing authorisation from transferor to transferee, cover letter
Spring Webinar: Cardiovascular Disease and Depresssion
Submitted by Aneta on 15 April 2024 - 15:36
We are pleased to announce the next webinar organised by EFIM Multimorbidity Working Group on the topic: "Cardiovascular Disease and Depresssion" will take place on Tuesday, 18 of June from 16:00 CET.
Register now and learn from the experts: Prof. Thomas Lüscher from the Royal Brompton Hospital in London and Prof. Claudia Hackl-Zuccarella from the University Hospital in Zürich will be talking about "Heart and Depression".
The webinar will be chaired by Prof. Edouard Battegay from the International Centre for Multimorbidity and Complexity in Basel.
Human medicines European public assessment report (EPAR): Xevudy, sotrovimab, Date of authorisation: 17/12/2021, Revision: 14, Status: Authorised
Submitted by Anonymous (not verified) on 15 April 2024 - 15:06
Human medicines European public assessment report (EPAR): Xevudy, sotrovimab, Date of authorisation: 17/12/2021, Revision: 14, Status: Authorised
Human medicines European public assessment report (EPAR): Translarna, ataluren, Date of authorisation: 31/07/2014, Revision: 23, Status: Authorised
Submitted by Anonymous (not verified) on 15 April 2024 - 14:52
Human medicines European public assessment report (EPAR): Translarna, ataluren, Date of authorisation: 31/07/2014, Revision: 23, Status: Authorised
Human medicines European public assessment report (EPAR): Scemblix, asciminib, Date of authorisation: 25/08/2022, Revision: 5, Status: Authorised
Submitted by Anonymous (not verified) on 15 April 2024 - 14:03
Human medicines European public assessment report (EPAR): Scemblix, asciminib, Date of authorisation: 25/08/2022, Revision: 5, Status: Authorised
Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 30, Status: Authorised
Submitted by Anonymous (not verified) on 15 April 2024 - 12:54
Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, Date of authorisation: 23/08/2012, Revision: 30, Status: Authorised
Human medicines European public assessment report (EPAR): Vargatef, nintedanib, Date of authorisation: 21/11/2014, Revision: 19, Status: Authorised
Submitted by Anonymous (not verified) on 15 April 2024 - 12:04
Human medicines European public assessment report (EPAR): Vargatef, nintedanib, Date of authorisation: 21/11/2014, Revision: 19, Status: Authorised
Human medicines European public assessment report (EPAR): Xospata, gilteritinib, Date of authorisation: 24/10/2019, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 15 April 2024 - 11:21
Human medicines European public assessment report (EPAR): Xospata, gilteritinib, Date of authorisation: 24/10/2019, Revision: 6, Status: Authorised